Clinical trial
A Phase I Dose-Escalation Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy
NCT00110500 is registered in ClinicalTrials.gov with Sangamo Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Dose-Escalation Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy
- Lead sponsor
- Sangamo Therapeutics
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 30, 2005
- Completion date
- January 31, 2008
- Enrollment
- 12 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
diabetic neuropathy